We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck (MRK) Stock Drops Despite Market Gains: Important Facts to Note
Read MoreHide Full Article
The most recent trading session ended with Merck (MRK - Free Report) standing at $93.43, reflecting a -1.37% shift from the previouse trading day's closing. The stock trailed the S&P 500, which registered a daily gain of 0.49%. At the same time, the Dow lost 0.2%, and the tech-heavy Nasdaq gained 1.22%.
The pharmaceutical company's stock has climbed by 9.46% in the past month, exceeding the Medical sector's loss of 1.05% and the S&P 500's loss of 8.15%.
The upcoming earnings release of Merck will be of great interest to investors. The company is predicted to post an EPS of $2.16, indicating a 4.35% growth compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $15.75 billion, down 0.16% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $9.01 per share and a revenue of $65.19 billion, representing changes of +17.78% and +1.6%, respectively, from the prior year.
Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for Merck. Such recent modifications usually signify the changing landscape of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, there's been a 0.09% fall in the Zacks Consensus EPS estimate. As of now, Merck holds a Zacks Rank of #4 (Sell).
Looking at valuation, Merck is presently trading at a Forward P/E ratio of 10.52. This represents a discount compared to its industry's average Forward P/E of 14.41.
One should further note that MRK currently holds a PEG ratio of 0.83. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. By the end of yesterday's trading, the Large Cap Pharmaceuticals industry had an average PEG ratio of 1.32.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 86, this industry ranks in the top 35% of all industries, numbering over 250.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Merck (MRK) Stock Drops Despite Market Gains: Important Facts to Note
The most recent trading session ended with Merck (MRK - Free Report) standing at $93.43, reflecting a -1.37% shift from the previouse trading day's closing. The stock trailed the S&P 500, which registered a daily gain of 0.49%. At the same time, the Dow lost 0.2%, and the tech-heavy Nasdaq gained 1.22%.
The pharmaceutical company's stock has climbed by 9.46% in the past month, exceeding the Medical sector's loss of 1.05% and the S&P 500's loss of 8.15%.
The upcoming earnings release of Merck will be of great interest to investors. The company is predicted to post an EPS of $2.16, indicating a 4.35% growth compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $15.75 billion, down 0.16% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $9.01 per share and a revenue of $65.19 billion, representing changes of +17.78% and +1.6%, respectively, from the prior year.
Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for Merck. Such recent modifications usually signify the changing landscape of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, there's been a 0.09% fall in the Zacks Consensus EPS estimate. As of now, Merck holds a Zacks Rank of #4 (Sell).
Looking at valuation, Merck is presently trading at a Forward P/E ratio of 10.52. This represents a discount compared to its industry's average Forward P/E of 14.41.
One should further note that MRK currently holds a PEG ratio of 0.83. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. By the end of yesterday's trading, the Large Cap Pharmaceuticals industry had an average PEG ratio of 1.32.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 86, this industry ranks in the top 35% of all industries, numbering over 250.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.